Thu, Feb 26, 2015, 8:46 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Momenta Pharmaceuticals Inc. Message Board

  • natgasinv natgasinv May 9, 2014 8:57 AM Flag

    Maxim starts with Buy and price target of $24

    Maxim Group initiates coverage on Momenta Pharmaceuticals (NASDAQ: MNTA) with a Buy rating and a price target of $24.00.

    Analyst Pamela Bassett comments, "We believe the company has a validated, scientific approach to the analysis and engineering of complex generic drugs that has been proven with the approval and launch of their fully interchangeable enoxaparin generic of Sanofi’s (SNY - $52.66 - NR) blood-thinner, Lovenox. We expect Momenta’s generic glatiramer acetate injection (M356) of Teva’s (TEVA - $50.00 - HOLD) Copaxone for the treatment of relapsing remitting multiple sclerosis (RRMS) to follow the regulatory path paved by enoxaparin. We anticipate FDA approval of M356, partnered with Sandoz, by June 2014 and the launch of an interchangeable version that we expect to rapidly capture market share, a boost to the company’s value and significant catalyst for the stock, in our view."

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
MNTA
13.94+0.05(+0.36%)Feb 26 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.